Search

everythinglearnresearchcommunity

for

Search:↓

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Brodalumab is more effective than ustekinumab in treating psoriasis.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

Radiotherapy was effective for treating a large scalp plaque of Bowen's disease when other treatments failed.

Bempikibart may help regrow hair in people with alopecia areata.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

The treatment was ineffective in humans.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Baricitinib improved hair loss and arthritis in a lupus patient.

Baricitinib works better than methotrexate for severe alopecia areata.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.